Insider Trading April 30, 2026 04:27 PM

BV Financial Director Joseph Galli Executes Stock Sale via IRA

Insider transaction filings reveal the sale of nearly 6,000 shares at prices near the company's yearly highs.

By Derek Hwang BVFL
BV Financial Director Joseph Galli Executes Stock Sale via IRA
BVFL

Joseph S. Galli, a member of the Board of Directors at BV Financial, Inc. (NASDAQ: BVFL), has completed a sale of common stock held through an individual retirement account (IRA). The transaction, which occurred on April 28, 2026, involved the disposal of 5,992 shares for a total consideration of $120,751. This movement comes as the company's stock trades at approximately $19.58, representing a significant 28% increase over the previous year and sitting close to its 52-week peak of $20.54.

Key Points

  • Insider liquidation of shares via an IRA by Director Joseph Galli.
  • BVFL stock shows strong annual performance with a 28% gain.
  • Company maintains a good financial health score despite recent selling activity.

Transaction Details and Shareholding Structure

According to recent filings, Joseph S. Galli's sale was conducted indirectly through his IRA. The shares were liquidated at price points ranging from $20.11 to $20.235 per share. Following this divestment, Mr. Galli maintains an indirect interest in BV Financial common stock via his IRA totaling 41,341 shares.

In addition to these indirect holdings, Mr. Galli's direct equity position remains substantial. He holds 80,309 shares of common stock directly, a figure that includes restricted stock subject to a vesting schedule. This specific tranche of restricted stock began vesting at an annual rate of 25% on September 6, 2025. Furthermore, his retirement plan holdings include an indirect interest of 12,100 shares.

Equity Incentives and Options

The director also maintains a significant position in stock options. Mr. Galli holds 36,746 direct stock options with a designated exercise price of $14.25 per share. These options are governed by a vesting schedule of 25% per year, which commenced on September 6, 2025, and they carry an expiration date of September 6, 2034.


Market Context and Financial Metrics

BV Financial (BVFL) has experienced notable price movement recently. The stock is currently trading at $19.58, which is in the vicinity of its 52-week high of $20.54. Over the last twelve months, the equity has seen a gain of 28%.

From a fundamental perspective, analysis from InvestingPro suggests that BVFL is currently trading below its Fair Value metrics. Additionally, the company is noted for maintaining a "GOOD" rating regarding its overall financial health score.


Key Points

  • Insider Liquidity: The sale of 5,992 shares via an IRA represents a specific liquidity event for a key director, though it does not deplete his total direct or indirect holdings.
  • Stock Performance: BVFL has demonstrated strong momentum, posting a 28% gain over the past year and trading near its annual high.
  • Valuation Discrepancy: Despite recent price appreciation, Fair Value metrics indicate that the stock may be undervalued relative to its intrinsic worth.

Impacted Sectors: These developments primarily affect the financial services sector and broader equity markets as investors monitor director sentiment and valuation models.


Risks and Uncertainties

  • Vesting Schedules: A portion of the director's holdings is tied to restricted stock and options that vest over time, creating future supply dynamics.
  • Price Volatility: While the stock has gained 28% recently, its proximity to the 52-week high may present resistance or volatility for the ticker.

Impacted Sectors: Such factors influence the financial sector's risk profiles and can impact institutional investor sentiment regarding BVFL.

Risks

  • Future supply considerations related to the vesting of restricted stock and options.
  • Potential price fluctuations as the stock nears its 52-week high.

More from Insider Trading

Marcus & Millichap Director Executes Substantial Common Stock Purchase May 4, 2026 Patterson-UTI CEO Executes Multi-Million Dollar Stock Sale Amidst Year-to-Date Surge May 4, 2026 Snowflake Director Michael Speiser Executes $7.18 Million in Stock Sales May 4, 2026 Edwards Lifesciences Executive Executes Stock Transactions Amid Recent Financial Growth May 4, 2026 Entrada Therapeutics President and COO Executes Stock Sale via Rule 10b5-1 Plan May 4, 2026